$1.32 Billion is the total value of Cormorant Asset Management, LP's 80 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 19.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TPTX | Sell | TURNING POINT THERAPEUTICS I | $186,938,000 | +88.2% | 2,484,220 | -32.9% | 14.14% | +85.3% |
| DSGN | Buy | DESIGN THERAPEUTICS INC | $77,000,000 | -7.5% | 5,500,000 | +6.7% | 5.82% | -8.9% |
| ERASCA INC | $58,516,000 | -35.2% | 10,505,554 | 0.0% | 4.42% | -36.2% | ||
| RXDX | Buy | PROMETHEUS BIOSCIENCES INC | $57,283,000 | -16.8% | 2,029,158 | +11.3% | 4.33% | -18.1% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $42,959,000 | -24.8% | 950,000 | -15.6% | 3.25% | -26.0% |
| RVMD | REVOLUTION MEDICINES INC | $38,884,000 | -23.6% | 1,995,066 | 0.0% | 2.94% | -24.8% | |
| BMEA | BIOMEA FUSION INC | $37,987,000 | +168.6% | 3,170,872 | 0.0% | 2.87% | +164.5% | |
| CCXI | Buy | CHEMOCENTRYX INC | $35,312,000 | +62.8% | 1,425,000 | +64.7% | 2.67% | +60.4% |
| ALT | New | ALTIMMUNE INC | $35,100,000 | – | 3,000,000 | +100.0% | 2.65% | – |
| XBI | New | SPDR SER TRcall | $33,422,000 | – | 450,000 | +100.0% | 2.53% | – |
| New | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $30,886,000 | – | 6,065,001 | +100.0% | 2.34% | – | |
| EWTX | Sell | EDGEWISE THERAPEUTICS INC | $30,646,000 | -32.5% | 3,850,000 | -17.8% | 2.32% | -33.6% |
| RNA | AVIDITY BIOSCIENCES INC | $29,236,000 | -21.3% | 2,012,115 | 0.0% | 2.21% | -22.5% | |
| GLUE | Sell | MONTE ROSA THERAPEUTICS INC | $28,949,000 | -31.2% | 2,993,717 | -0.3% | 2.19% | -32.3% |
| New | ARCELLX INC | $27,572,000 | – | 1,525,000 | +100.0% | 2.08% | – | |
| TARS | Buy | TARSUS PHARMACEUTICALS INC | $27,375,000 | +18.3% | 1,875,000 | +36.3% | 2.07% | +16.5% |
| AVTE | Sell | AEROVATE THERAPEUTICS INC | $27,051,000 | -19.4% | 1,730,691 | -5.5% | 2.04% | -20.6% |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $26,941,000 | +184.0% | 184,894 | +131.1% | 2.04% | +179.8% |
| ACET | Buy | ADICET BIO INC | $26,280,000 | +75.5% | 1,800,000 | +140.0% | 1.99% | +72.8% |
| PHVS | Buy | PHARVARIS N V | $25,326,000 | +103.9% | 1,145,953 | +67.3% | 1.92% | +100.7% |
| FMTX | Sell | FORMA THERAPEUTICS HLDGS INC | $21,856,000 | -42.2% | 3,172,204 | -22.0% | 1.65% | -43.1% |
| HZNP | Buy | HORIZON THERAPEUTICS PUB L | $21,336,000 | +102.8% | 267,500 | +167.5% | 1.61% | +99.6% |
| Sell | TANGO THERAPEUTICS INC | $20,421,000 | -45.0% | 4,507,843 | -8.0% | 1.54% | -45.8% | |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $20,139,000 | +389.9% | 300,000 | +500.0% | 1.52% | +382.0% |
| AXNX | AXONICS INC | $18,261,000 | -9.5% | 322,240 | 0.0% | 1.38% | -10.8% | |
| KRTX | Sell | KARUNA THERAPEUTICS INC | $15,814,000 | -16.8% | 125,000 | -16.7% | 1.20% | -18.1% |
| CYTK | CYTOKINETICS INC | $15,716,000 | +6.7% | 400,000 | 0.0% | 1.19% | +5.1% | |
| ITCI | Buy | INTRA-CELLULAR THERAPIES INC | $15,697,000 | +71.0% | 275,000 | +83.3% | 1.19% | +68.4% |
| VECT | Buy | VECTIVBIO HLDG AG | $15,338,000 | +56.7% | 2,840,389 | +36.7% | 1.16% | +54.3% |
| Buy | GREENLIGHT BIOSCIENCS HLDS P | $15,234,000 | -75.4% | 6,960,540 | +3.7% | 1.15% | -75.8% | |
| STOK | STOKE THERAPEUTICS INC | $14,370,000 | -37.2% | 1,087,807 | 0.0% | 1.09% | -38.2% | |
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $14,256,000 | -36.2% | 2,927,273 | +17.6% | 1.08% | -37.1% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $13,340,000 | -16.2% | 1,469,179 | -6.4% | 1.01% | -17.5% |
| RAIN | RAIN THERAPEUTICS INC | $12,936,000 | +9.7% | 2,326,660 | 0.0% | 0.98% | +7.9% | |
| Sell | IMMUNEERING CORP | $12,368,000 | -17.0% | 2,286,181 | -0.7% | 0.94% | -18.3% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $11,951,000 | -13.2% | 868,550 | 0.0% | 0.90% | -14.6% | |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $11,694,000 | – | 475,000 | +100.0% | 0.88% | – |
| AVIR | ATEA PHARMACEUTICALS INC | $10,985,000 | -1.7% | 1,547,181 | 0.0% | 0.83% | -3.1% | |
| VERV | VERVE THERAPEUTICS INC | $10,707,000 | -33.0% | 700,710 | 0.0% | 0.81% | -34.0% | |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $10,153,000 | -45.1% | 877,500 | -12.2% | 0.77% | -45.9% |
| KZR | New | KEZAR LIFE SCIENCES INC | $9,924,000 | – | 1,200,000 | +100.0% | 0.75% | – |
| Sell | VENTYX BIOSCIENCES INC | $9,547,000 | -10.4% | 780,643 | -0.6% | 0.72% | -11.7% | |
| OLMA | OLEMA PHARMACEUTICALS INC | $8,474,000 | -4.5% | 2,082,000 | 0.0% | 0.64% | -5.9% | |
| AXSM | New | AXSOME THERAPEUTICS INC | $7,852,000 | – | 205,000 | +100.0% | 0.59% | – |
| LBPH | LONGBOARD PHARMACEUTICALS IN | $7,024,000 | -42.1% | 2,273,221 | 0.0% | 0.53% | -43.0% | |
| COGT | New | COGENT BIOSCIENCES INC | $6,765,000 | – | 750,000 | +100.0% | 0.51% | – |
| AMAM | AMBRX BIOPHARMA INCsponsored ads | $6,589,000 | -35.7% | 2,486,386 | 0.0% | 0.50% | -36.7% | |
| GHRS | GH RESEARCH PLCordinary shares | $6,069,000 | -45.4% | 608,123 | 0.0% | 0.46% | -46.3% | |
| BCAB | BIOATLA INC | $5,809,000 | -43.0% | 2,038,215 | 0.0% | 0.44% | -43.9% | |
| ALXO | ALX ONCOLOGY HLDGS INC | $5,761,000 | -52.1% | 712,079 | 0.0% | 0.44% | -52.8% | |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $5,392,000 | – | 200,000 | +100.0% | 0.41% | – |
| Sell | TYRA BIOSCIENCES INC | $5,320,000 | -34.4% | 743,988 | -1.8% | 0.40% | -35.4% | |
| TALS | TALARIS THERAPEUTICS INC | $5,298,000 | -54.2% | 1,174,723 | 0.0% | 0.40% | -54.8% | |
| ASND | ASCENDIS PHARMA A/Ssponsored adr | $4,648,000 | -20.8% | 50,000 | 0.0% | 0.35% | -22.2% | |
| PLRX | PLIANT THERAPEUTICS INC | $3,864,000 | +14.3% | 482,413 | 0.0% | 0.29% | +12.3% | |
| AKRO | AKERO THERAPEUTICS INC | $3,816,000 | -33.4% | 403,787 | 0.0% | 0.29% | -34.3% | |
| Buy | ICOSAVAX INC | $3,732,000 | +24.3% | 651,393 | +52.8% | 0.28% | +22.6% | |
| ELDN | ELEDON PHARMACEUTICALS INC | $3,184,000 | -38.1% | 1,305,095 | 0.0% | 0.24% | -39.0% | |
| ELEV | Buy | ELEVATION ONCOLOGY INC | $2,776,000 | -44.5% | 1,983,168 | +0.0% | 0.21% | -45.3% |
| KROS | KEROS THERAPEUTICS INC | $2,763,000 | -49.2% | 100,000 | 0.0% | 0.21% | -50.0% | |
| YMAB | Y-MABS THERAPEUTICS INC | $2,270,000 | +27.4% | 150,000 | 0.0% | 0.17% | +25.5% | |
| AKUS | AKOUOS INC | $1,850,000 | -1.3% | 394,500 | 0.0% | 0.14% | -2.8% | |
| GLTO | GALECTO INC | $1,765,000 | -21.4% | 1,020,238 | 0.0% | 0.13% | -22.7% | |
| GOSS | GOSSAMER BIO INC | $1,660,000 | -3.6% | 198,382 | 0.0% | 0.13% | -4.5% | |
| VIGIL NEUROSCIENCE INC | $1,591,000 | -62.2% | 616,786 | 0.0% | 0.12% | -62.8% | ||
| PYXIS ONCOLOGY INC | $1,592,000 | -41.1% | 668,854 | 0.0% | 0.12% | -42.0% | ||
| CABA | CABALETTA BIO INC | $1,224,000 | -47.8% | 1,154,424 | 0.0% | 0.09% | -48.3% | |
| MGTX | MEIRAGTX HLDGS PLC | $1,136,000 | -45.3% | 150,000 | 0.0% | 0.09% | -46.2% | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $1,110,000 | -32.1% | 392,167 | 0.0% | 0.08% | -33.3% | |
| CMMB | CHEMOMAB THERAPEUTICS LTDsponsored ads | $1,066,000 | -22.9% | 288,168 | 0.0% | 0.08% | -23.6% | |
| HARP | HARPOON THERAPEUTICS INC | $1,033,000 | -61.6% | 540,600 | 0.0% | 0.08% | -62.1% | |
| ANAB | ANAPTYSBIO INC | $1,015,000 | -17.9% | 50,000 | 0.0% | 0.08% | -18.9% | |
| RENOVACOR INC | $1,014,000 | -52.2% | 500,000 | 0.0% | 0.08% | -52.8% | ||
| GELESIS HLDGS INC | $970,000 | -64.7% | 626,108 | 0.0% | 0.07% | -65.4% | ||
| ASTRIA THERAPEUTICS INC | $900,000 | -55.3% | 300,000 | 0.0% | 0.07% | -56.1% | ||
| BCEL | Sell | ATRECA INC | $571,000 | -77.5% | 319,057 | -60.1% | 0.04% | -77.9% |
| GRPH | Sell | GRAPHITE BIO INC | $549,000 | -47.0% | 199,547 | -1.8% | 0.04% | -47.5% |
| IMV | IMV INC | $155,000 | -54.0% | 234,374 | 0.0% | 0.01% | -53.8% | |
| ORTX | ORCHARD THERAPEUTICS PLCads | $150,000 | -18.0% | 256,649 | 0.0% | 0.01% | -21.4% | |
| XFOR | X4 PHARMACEUTICALS INC | $100,000 | -45.1% | 103,980 | 0.0% | 0.01% | -42.9% | |
| DTIL | Exit | PRECISION BIOSCIENCES INC | $0 | – | -346,524 | -100.0% | -0.08% | – |
| ITOS | Exit | ITEOS THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.25% | – |
| BEAM | Exit | BEAM THERAPEUTICS INC | $0 | – | -90,045 | -100.0% | -0.40% | – |
| PRAX | Exit | PRAXIS PRECISION MEDICINES I | $0 | – | -752,406 | -100.0% | -0.59% | – |
| IGMS | Exit | IGM BIOSCIENCES INC | $0 | – | -402,200 | -100.0% | -0.82% | – |
| HLXA | Exit | HELIX ACQUISITION CORP | $0 | – | -3,280,000 | -100.0% | -2.56% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.